Dual Antiplatelet Therapy After Aneurysm Embolization
You should continue taking both aspirin 81 mg and clopidogrel 75 mg daily for at least 3-6 months after your aneurysm embolization, then transition to aspirin alone indefinitely. At 6 weeks post-procedure, you are still within the critical period where dual antiplatelet therapy (DAPT) is essential to prevent thrombotic complications.
Duration of Dual Antiplatelet Therapy
The evidence for aneurysm embolization differs significantly from cardiac stenting guidelines. While the provided guidelines primarily address coronary interventions 1, 2, 3, 4, 5, the neurovascular literature demonstrates specific requirements for cerebral aneurysm treatment:
- Minimum DAPT duration: 3-6 months after stent-assisted coil embolization or flow diversion 6, 7, 8
- Research shows that discontinuing clopidogrel at 6 weeks carries a 5% risk of ischemic events 6
- Studies demonstrate that continuing clopidogrel for at least 3 months significantly reduces thromboembolic complications without increasing hemorrhagic risk 9
The critical finding: Two ischemic events in one study occurred within the first 2 weeks after stopping clopidogrel at 6 weeks 6. This suggests your current 6-week timepoint is particularly high-risk for premature discontinuation.
Specific Recommendations for Your Situation
Continue Current Regimen:
- Aspirin 81 mg daily - continue indefinitely 10
- Clopidogrel 75 mg daily - continue for at minimum 3 months total (you're at 6 weeks), ideally 6 months 7, 8, 9
Transition Plan (at 3-6 months):
- Stop clopidogrel after completing 3-6 months of DAPT
- Continue aspirin 81 mg daily indefinitely 11, 12
Evidence-Based Rationale
The neurovascular literature consistently shows:
Antiplatelet therapy before and after embolization reduces symptomatic thromboembolic complications from 16% to 1.9% 11
Clopidogrel therapy ≤6 months is associated with higher rates of thrombotic events compared to longer duration 8
High-risk features requiring longer DAPT include 6:
- Cardiovascular risk factors (hypertension, diabetes, smoking)
- Atypical aneurysm features
- Flow diversion devices (vs. simple coiling)
- Technical complications during procedure
Survival analysis demonstrates better outcomes with at least 3 months of antiplatelet therapy, with recommendations to continue DAPT for 12 months when possible 9
Important Caveats
Do NOT stop clopidogrel if you have:
- Cardiovascular risk factors (hypertension, diabetes, high cholesterol, smoking history)
- Complex aneurysm anatomy
- Flow diversion device (Pipeline or similar) rather than simple coiling
- Any stent placement during your procedure
Bleeding Risk Considerations:
The FDA label for clopidogrel warns that discontinuation increases cardiovascular event risk 10. While this primarily addresses cardiac patients, the principle applies to neurovascular stenting. If surgery is needed, clopidogrel should be stopped at least 5 days beforehand 10, but this requires coordination with your neurosurgeon.
When to Contact Your Physician Immediately:
- New neurological symptoms (weakness, speech changes, vision changes)
- Severe headache
- Signs of bleeding (unusual bruising, blood in stool/urine, persistent bleeding)
- Before any surgical or dental procedures 10
Practical Management
Contact your interventional neuroradiologist or neurosurgeon to confirm:
- The specific type of device used (coils alone vs. stent-assisted vs. flow diversion)
- Your individual cardiovascular risk profile
- The planned total duration of DAPT for your case
The standard approach based on current evidence would be continuing both medications for at least 3 months total (another 6 weeks minimum from now), preferably 6 months, then transitioning to aspirin monotherapy indefinitely 7, 8, 9.